| Description | Dopropidil is a new anti-angina pectoris calcium regulator, which has intracellular calcium antagonist activity and anti-ischemic effects in various predicted animal models. |
| In vitro | In the calcium-free medium (IC50 = 30.0 uM), dopredil can inhibit caffeine-induced contraction of rabbit renal arteries. Dopredil inhibits norepinephrine (NE)-induced responses with IC50 of 2.7 and 29.8 uM, respectively. At 3 μM and 10 μM, dopredil significantly reduced the maximum increase in diastolic pressure caused by veratrine (IC50 = 2.8 μM). |
| In vivo | Dopamine (1 and 2.5 mg/kg) dose-dependently reduced electrical (ST segment elevation), biochemical (lactate production and potassium release) and mechanical (myocardial segment contractility loss) disturbances caused by ischemia in anesthetized dogs. Intraduodenal administration of dopredil (50 mg/kg) can significantly reduce tachycardia caused by isoproterenol. This effect is evident between 15 and 120 minutes after application of the compound, indicating rapid absorption and long duration of action. In awake dogs, doprodil (12-14 mg/kg p.o.) can reduce the resting heart rate by about 10 beats/minute. |
| molecular weight | 321.5 |
| Molecular formula | C20H35NO2 |
| CAS | 79700-61-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. J. Planellas, et al. Dopropidil, A Novel Antianginal Calcium Modulating Agent. Cardiovascular Drug Reviews. Vol.12, No.3, pp. 208-224. |